The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation
Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand’s Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program had a...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Public Library of Science
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777547/ |
| id |
pubmed-4777547 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-47775472016-03-10 The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation Posuwan, Nawarat Wanlapakorn, Nasamon Sa-nguanmoo, Pattaratida Wasitthankasem, Rujipat Vichaiwattana, Preeyaporn Klinfueng, Sirapa Vuthitanachot, Viboonsak Sae-lao, Siriporn Foonoi, Monthana Fakthongyoo, Apinya Makaroon, Jamorn Srisingh, Klaita Asawarachun, Duangporn Owatanapanich, Somchai Wutthiratkowit, Norra Tohtubtiang, Kraisorn Yoocharoen, Pornsak Vongpunsawad, Sompong Poovorawan, Yong Research Article Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand’s Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program had a carrier rate of less than 1%, compared with 5–6% before implementation. In 2014 we performed hepatitis B serosurveys among 5964 subjects in the different geographic regions of the country to evaluate the long-term immunogenicity and impact of universal hepatitis B vaccination in newborns as part of the 22-year EPI program, by assessing HBsAg, anti-HBc and anti-HBs seropositivity status. The number of HB virus (HBV) carriers, both children and young adults, who were born after universal HB vaccination was markedly reduced. The carrier rates among the age groups 6 months to 5 years, 5–10, 11–20, 21–30, 31–40, 41–50 and >50 years were respectively 0.1, 0.29, 0.69, 3.12, 3.78, 4.67 and 5.99%. The seropositivity rate for HBsAg in the post-EPI group was 0.6%, whereas in the pre-EPI group it was as high as 4.5% (p<0.001). HBV infection by means of detectable anti-HBc had also drastically declined in the population born after the HB vaccine was integrated into the EPI program. We estimated that the total number of HBV carriers amounted to 2.22 million, or 3.48% of the total population, most of whom are adults. The HB vaccine is the first vaccine shown to be effective in preventing the occurrence of chronic liver disease and hepatocellular carcinoma. Universal vaccination campaign will contribute to the eventual eradication of HBV-associated disease. Public Library of Science 2016-03-03 /pmc/articles/PMC4777547/ /pubmed/26938736 http://dx.doi.org/10.1371/journal.pone.0150499 Text en © 2016 Posuwan et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Posuwan, Nawarat Wanlapakorn, Nasamon Sa-nguanmoo, Pattaratida Wasitthankasem, Rujipat Vichaiwattana, Preeyaporn Klinfueng, Sirapa Vuthitanachot, Viboonsak Sae-lao, Siriporn Foonoi, Monthana Fakthongyoo, Apinya Makaroon, Jamorn Srisingh, Klaita Asawarachun, Duangporn Owatanapanich, Somchai Wutthiratkowit, Norra Tohtubtiang, Kraisorn Yoocharoen, Pornsak Vongpunsawad, Sompong Poovorawan, Yong |
| spellingShingle |
Posuwan, Nawarat Wanlapakorn, Nasamon Sa-nguanmoo, Pattaratida Wasitthankasem, Rujipat Vichaiwattana, Preeyaporn Klinfueng, Sirapa Vuthitanachot, Viboonsak Sae-lao, Siriporn Foonoi, Monthana Fakthongyoo, Apinya Makaroon, Jamorn Srisingh, Klaita Asawarachun, Duangporn Owatanapanich, Somchai Wutthiratkowit, Norra Tohtubtiang, Kraisorn Yoocharoen, Pornsak Vongpunsawad, Sompong Poovorawan, Yong The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation |
| author_facet |
Posuwan, Nawarat Wanlapakorn, Nasamon Sa-nguanmoo, Pattaratida Wasitthankasem, Rujipat Vichaiwattana, Preeyaporn Klinfueng, Sirapa Vuthitanachot, Viboonsak Sae-lao, Siriporn Foonoi, Monthana Fakthongyoo, Apinya Makaroon, Jamorn Srisingh, Klaita Asawarachun, Duangporn Owatanapanich, Somchai Wutthiratkowit, Norra Tohtubtiang, Kraisorn Yoocharoen, Pornsak Vongpunsawad, Sompong Poovorawan, Yong |
| author_sort |
Posuwan, Nawarat |
| title |
The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation |
| title_short |
The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation |
| title_full |
The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation |
| title_fullStr |
The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation |
| title_full_unstemmed |
The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation |
| title_sort |
success of a universal hepatitis b immunization program as part of thailand’s epi after 22 years’ implementation |
| description |
Hepatitis B vaccination for newborns was introduced in two provinces in 1988 as part of Thailand’s Expanded Program on Immunization (EPI), and extended to the whole country in 1992. Our previous studies showed that children and adolescents who were born after the implementation of this program had a carrier rate of less than 1%, compared with 5–6% before implementation. In 2014 we performed hepatitis B serosurveys among 5964 subjects in the different geographic regions of the country to evaluate the long-term immunogenicity and impact of universal hepatitis B vaccination in newborns as part of the 22-year EPI program, by assessing HBsAg, anti-HBc and anti-HBs seropositivity status. The number of HB virus (HBV) carriers, both children and young adults, who were born after universal HB vaccination was markedly reduced. The carrier rates among the age groups 6 months to 5 years, 5–10, 11–20, 21–30, 31–40, 41–50 and >50 years were respectively 0.1, 0.29, 0.69, 3.12, 3.78, 4.67 and 5.99%. The seropositivity rate for HBsAg in the post-EPI group was 0.6%, whereas in the pre-EPI group it was as high as 4.5% (p<0.001). HBV infection by means of detectable anti-HBc had also drastically declined in the population born after the HB vaccine was integrated into the EPI program. We estimated that the total number of HBV carriers amounted to 2.22 million, or 3.48% of the total population, most of whom are adults. The HB vaccine is the first vaccine shown to be effective in preventing the occurrence of chronic liver disease and hepatocellular carcinoma. Universal vaccination campaign will contribute to the eventual eradication of HBV-associated disease. |
| publisher |
Public Library of Science |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777547/ |
| _version_ |
1613547166419124224 |